Corporate highlights

• Privately-held Montreal-based biotechnology company
• Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets
• Currently having one clinical-stage program with phase I data
• Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology
• Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline
• Established strategic partnerships to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies